Business
Resverlogix Further Strengthens the Board of Directors and Appoints a New Chairman
Resverlogix Further Strengthens the Board of Directors and Appoints a New Chairman ...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nResverlogix Further Strengthens the Board of Directors and Appoints a New Chairman\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nResverlogix Further Strengthens the Board of Directors and Appoints a New Chairman\nCanada NewsWire\nCALGARY, April 4, 2016\n\n\n\nCALGARY, April 4, 2016 /CNW/ - Resverlogix Corp. (the \"Corporation\") (TSX:RVX) is pleased to announce that  Mrs. Norma K. Biln, Chief Executive Officer of Augurex, and  Mr. Shawn Lu, Chief Financial Officer of Hepalink USA Inc. have been appointed to Resverlogix's Board of Directors. \n\n\"We are pleased to welcome these two experienced life science business leaders to Resverlogix's Board of Directors,\" stated Mr. Donald McCaffrey, President and Chief Executive Officer. \"The addition to our Board with the appointments of Ms. Biln and Mr. Lu will ensure that Resverlogix will continue to benefit from a diversity of knowledge. The combined experience of their respective careers will be a tremendous asset to the company,\" further commented Mr. McCaffrey.\n\nOn the subject of their appointments, Ms. Biln stated, \"It is a very exciting time to be joining Resverlogix's Board of Directors during the commencement of their phase 3 clinical trial in an indication with such a high unmet medical need. The cutting edge R&D and positive strategic energy throughout the organization is some of the best I have ever seen.\"  Mr. Lu commented, \"It is a great pleasure to join the Board and further foster the long-term partnership between Hepalink and Resverlogix. I look forward to sharing expertise amongst our respective companies.\"\n\nMs. Biln is the Chief Executive Officer and Co-Founder of Augurex. She has 22 years of experience in the pharmaceutical and biotech industries, commencing her career in clinical research with Pfizer Pharmaceuticals and held several positions in sales management, marketing and market access with Pfizer, Amgen and Abbott Laboratories where she won several regional and national level awards for top performance. Ms. Biln later joined Stressgen Biotechnologies as Director o...